$PDC

FTX-linked fintech Perpetuals (PDC) plans tokenized stock trading under SEC framework

Nasdaq-listed Perpetuals.com (PDC) plans to offer tokenized U.S. stocks under the SEC's new innovation exemption, following a similar move by OKX-ICE. CEO Patrick Gruhn previously worked with FTX and Binance on stock-linked tokens. Trading could start in mid-November, pending technical and compliance preparations.

Original reporting
Published Oct 14, 2026, 2:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 3:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$PDC
Bullish
high confidence
Mentioned
$PDC
Relevance
6/10
AlphAI data visualization · based on coindesk.com
Decision brief

The 30-second read

$PDCBullishMed
01

Why it matters

Perpetuals.com's filing marks the second attempt to use this framework, following an OKX‑ICE joint venture, highlighting growing interest in blockchain‑based equity trading.

02

Market read

First‑report of a regulated tokenized stock platform could create a new asset class and affect crypto‑related equities.

03

What to watch

Technical and compliance hurdles may postpone launch beyond the stated mid‑November timeline.

Relevance 6/10Novelty 7/10Timing: mid‑November launch window

Background

The SEC's five‑year innovation exemption allows blockchain platforms to trade tokenized U.S. equities without traditional exchange registration.

Company-level read

Ticker impact

$PDCBullishHigh confidence
Context

Perpetuals.com filed a notice to launch a tokenized U.S. stock marketplace under the SEC's innovation exemption.

Expected impact

potential upside as investors price in future tokenized stock trading revenue.

Evidence & confidence

First‑report of a SEC‑approved framework; no comparable venue yet, creating a novel revenue stream.

Market effects

May spur other fintechs to seek similar SEC exemptions, expanding the tokenized securities niche.

U.S. crypto‑related stocks could see modest gains as regulatory clarity improves.

Sets a precedent for tokenized equity markets worldwide, potentially influencing overseas regulators.

Counterpoint

If regulatory scrutiny tightens, the venue could face delays, limiting near‑term upside.

Key entities

  • Perpetuals.com

    Nasdaq‑listed fintech planning tokenized stock marketplace.

  • SEC

    U.S. Securities and Exchange Commission, issuer of the innovation exemption.

Related articles

$PDCMedAI 8/10

Perpetuals.com Ltd: Perpetual Markets MTF Secures MiCA Authorization in Cyprus, Expanding Its Regulated European Trading Venue Into Crypto

Perpetuals.com Ltd (Nasdaq: PDC) said its Cyprus unit, Perpetual Markets MTF, received CySEC approval under the EU MiCA framework to run a regulated crypto-asset trading platform. The authorization covers custody, trading, order execution, and crypto transfers, enabling cross-border EU services via MiCA notifications.

$VHigh

Visa eyes domestic card clearing

Visa received preliminary approval to establish a domestic bank card clearing institution in China, according to the People's Bank of China. CEO Ryan McInerney called this a significant step, allowing Visa to issue Visa-branded payment products in China once operations begin. The subsidiary has one year to complete preparations before applying for a license. Visa has long provided cross-border services but cannot issue RMB cards without the license.

$CVSMed

CVS opioid lawsuit settlement — 315 Million Dollar Deal Reached

CVS and its affiliates agreed to pay $315 million to the U.S. Department of Justice to settle a lawsuit over illegal opioid dispensing. The DOJ alleged CVS filled prescriptions without proper verification, leading to federal health insurance fraud. CVS denied wrongdoing but settled to avoid litigation costs. The settlement includes fines and mandatory safety measures for future opioid prescriptions.

$CVSMed

CVS paying $315M to settle charges over opioid prescriptions

CVS Pharmacy Inc. will pay $315 million to settle charges of illegally filling opioid prescriptions and submitting false claims to the federal government, according to the Department of Justice. The settlement resolves allegations from 2013 to 2025, with CVS disputing the claims and stating the payment is not an admission of wrongdoing. The case was led by a whistleblower, a former CVS employee.